Development of a RIPK1 degrader to enhance antitumor immunity
2024

Development of a RIPK1 degrader to enhance antitumor immunity

Sample size: 8 publication 10 minutes Evidence: high

Author Information

Author(s): Yu Xin, Lu Dong, Qi Xiaoli, Paudel Rishi Ram, Lin Hanfeng, Holloman Bryan L., Jin Feng, Xu Longyong, Ding Lang, Peng Weiyi, Wang Meng C., Chen Xi, Wang Jin

Primary Institution: Baylor College of Medicine

Hypothesis

Can targeting RIPK1 improve responses to immune checkpoint inhibitors in cancer therapy?

Conclusion

The RIPK1 degrader LD4172 enhances antitumor immunity and sensitizes tumors to anti-PD1 therapy.

Supporting Evidence

  • LD4172 induces potent RIPK1 degradation in various cancer cell lines.
  • LD4172 enhances tumor-infiltrating lymphocyte responses.
  • LD4172 sensitizes tumors to anti-PD1 therapy.
  • LD4172 triggers immunogenic cell death in B16F10 tumors.
  • LD4172 shows high specificity for RIPK1 degradation.

Takeaway

Scientists created a new drug that helps the immune system fight cancer better by breaking down a protein called RIPK1.

Methodology

The study used PROTAC technology to develop and test the RIPK1 degrader LD4172 in various cancer models.

Limitations

The pharmacokinetic properties of LD4172 may limit its effectiveness in vivo.

Participant Demographics

Female C57BL/6J mice were used in the experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/s41467-024-55006-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication